vs
Side-by-side financial comparison of StepStone Group Inc. (STEP) and Bio-Techne (TECH). Click either name above to swap in a different company.
StepStone Group Inc. is the larger business by last-quarter revenue ($586.5M vs $295.9M, roughly 2.0× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs -21.0%, a 33.9% gap on every dollar of revenue. On growth, StepStone Group Inc. posted the faster year-over-year revenue change (73.0% vs -6.4%). Over the past eight quarters, StepStone Group Inc.'s revenue compounded faster (28.2% CAGR vs 4.2%).
Rosetta Stone Inc. is an American education technology software company that develops language, literacy and brain-fitness software. Best known for its language-learning products, in 2013, the company expanded beyond language into education-technology with its acquisitions of Livemocha, Lexia Learning, Fit Brains, and Tell Me More. In 2021, it became a subsidiary of IXL Learning.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
STEP vs TECH — Head-to-Head
Income Statement — Q3 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $586.5M | $295.9M |
| Net Profit | $-123.5M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | -33.2% | 18.4% |
| Net Margin | -21.0% | 12.8% |
| Revenue YoY | 73.0% | -6.4% |
| Net Profit YoY | 35.7% | 68.3% |
| EPS (diluted) | $-1.55 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $586.5M | $295.9M | ||
| Q3 25 | $454.2M | — | ||
| Q2 25 | $364.3M | $317.0M | ||
| Q1 25 | $377.7M | $316.2M | ||
| Q4 24 | $339.0M | $297.0M | ||
| Q3 24 | $271.7M | $289.5M | ||
| Q2 24 | $186.4M | $306.1M | ||
| Q1 24 | $356.8M | $303.4M |
| Q4 25 | $-123.5M | $38.0M | ||
| Q3 25 | $-366.1M | — | ||
| Q2 25 | $-38.4M | $-17.7M | ||
| Q1 25 | $-18.5M | $22.6M | ||
| Q4 24 | $-192.0M | $34.9M | ||
| Q3 24 | $17.6M | $33.6M | ||
| Q2 24 | $13.3M | $40.6M | ||
| Q1 24 | $30.8M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | -33.2% | 18.4% | ||
| Q3 25 | -148.8% | — | ||
| Q2 25 | -5.6% | -7.5% | ||
| Q1 25 | 2.6% | 12.2% | ||
| Q4 24 | -101.7% | 16.0% | ||
| Q3 24 | 21.3% | 13.8% | ||
| Q2 24 | 29.4% | 15.0% | ||
| Q1 24 | 26.5% | 22.1% |
| Q4 25 | -21.0% | 12.8% | ||
| Q3 25 | -80.6% | — | ||
| Q2 25 | -10.5% | -5.6% | ||
| Q1 25 | -4.9% | 7.1% | ||
| Q4 24 | -56.6% | 11.7% | ||
| Q3 24 | 6.5% | 11.6% | ||
| Q2 24 | 7.2% | 13.3% | ||
| Q1 24 | 8.6% | 16.2% |
| Q4 25 | $-1.55 | $0.24 | ||
| Q3 25 | $-4.66 | — | ||
| Q2 25 | $-0.49 | $-0.11 | ||
| Q1 25 | $-0.37 | $0.14 | ||
| Q4 24 | $-2.61 | $0.22 | ||
| Q3 24 | $0.26 | $0.21 | ||
| Q2 24 | $0.20 | $0.26 | ||
| Q1 24 | $0.47 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | $270.2M | $260.0M |
| Stockholders' EquityBook value | $-378.8M | $2.0B |
| Total Assets | $5.2B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M | ||
| Q1 24 | — | $145.3M |
| Q4 25 | $270.2M | $260.0M | ||
| Q3 25 | $269.9M | — | ||
| Q2 25 | $269.6M | $346.0M | ||
| Q1 25 | $269.3M | $330.0M | ||
| Q4 24 | $168.9M | $300.0M | ||
| Q3 24 | $172.3M | $300.0M | ||
| Q2 24 | $172.1M | $319.0M | ||
| Q1 24 | $148.8M | $389.0M |
| Q4 25 | $-378.8M | $2.0B | ||
| Q3 25 | $-233.5M | — | ||
| Q2 25 | $153.9M | $1.9B | ||
| Q1 25 | $179.4M | $2.0B | ||
| Q4 24 | $209.8M | $2.1B | ||
| Q3 24 | $397.5M | $2.1B | ||
| Q2 24 | $366.9M | $2.1B | ||
| Q1 24 | $324.5M | $2.0B |
| Q4 25 | $5.2B | $2.5B | ||
| Q3 25 | $5.3B | — | ||
| Q2 25 | $4.8B | $2.6B | ||
| Q1 25 | $4.6B | $2.6B | ||
| Q4 24 | $4.3B | $2.7B | ||
| Q3 24 | $4.0B | $2.7B | ||
| Q2 24 | $3.8B | $2.7B | ||
| Q1 24 | $3.8B | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.75× | 0.18× | ||
| Q1 25 | 1.50× | 0.16× | ||
| Q4 24 | 0.81× | 0.14× | ||
| Q3 24 | 0.43× | 0.14× | ||
| Q2 24 | 0.47× | 0.15× | ||
| Q1 24 | 0.46× | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $27.2M | — |
| Free Cash FlowOCF − Capex | $26.7M | — |
| FCF MarginFCF / Revenue | 4.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $18.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.2M | — | ||
| Q3 25 | $16.2M | — | ||
| Q2 25 | $46.3M | $98.2M | ||
| Q1 25 | $-66.5M | $41.1M | ||
| Q4 24 | $27.6M | $84.3M | ||
| Q3 24 | $53.7M | $63.9M | ||
| Q2 24 | $50.2M | $75.5M | ||
| Q1 24 | $7.6M | $81.0M |
| Q4 25 | $26.7M | — | ||
| Q3 25 | $15.9M | — | ||
| Q2 25 | $45.2M | $93.3M | ||
| Q1 25 | $-69.2M | $31.0M | ||
| Q4 24 | $27.0M | $77.5M | ||
| Q3 24 | $52.4M | $54.7M | ||
| Q2 24 | $49.6M | $57.5M | ||
| Q1 24 | $6.7M | $64.5M |
| Q4 25 | 4.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 12.4% | 29.4% | ||
| Q1 25 | -18.3% | 9.8% | ||
| Q4 24 | 8.0% | 26.1% | ||
| Q3 24 | 19.3% | 18.9% | ||
| Q2 24 | 26.6% | 18.8% | ||
| Q1 24 | 1.9% | 21.3% |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.3% | 1.5% | ||
| Q1 25 | 0.7% | 3.2% | ||
| Q4 24 | 0.2% | 2.3% | ||
| Q3 24 | 0.5% | 3.2% | ||
| Q2 24 | 0.3% | 5.9% | ||
| Q1 24 | 0.3% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | 3.05× | 1.90× | ||
| Q2 24 | 3.76× | 1.86× | ||
| Q1 24 | 0.25× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
STEP
| Other | $210.1M | 36% |
| Management And Advisory Fees Net Focused Commingled Funds | $143.3M | 24% |
| Carried Interest Allocation Focused Commingled Funds | $85.1M | 15% |
| Carried Interest Allocation Separately Managed Accounts | $63.6M | 11% |
| Carried Interest Allocation Realized | $46.7M | 8% |
| Management And Advisory Fees Net Advisory And Other Services | $18.3M | 3% |
| Legacy Carried Interest Allocation Focused Commingled Funds | $10.3M | 2% |
| Income Based Incentive Fees | $6.0M | 1% |
| Management And Advisory Fees Net Fund Reimbursement Revenues | $3.1M | 1% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
